These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR; Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093 [TBL] [Abstract][Full Text] [Related]
5. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M; Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178 [TBL] [Abstract][Full Text] [Related]
6. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. Safaeian M; Porras C; Schiffman M; Rodriguez AC; Wacholder S; Gonzalez P; Quint W; van Doorn LJ; Sherman ME; Xhenseval V; Herrero R; Hildesheim A; J Natl Cancer Inst; 2010 Nov; 102(21):1653-62. PubMed ID: 20944077 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A; J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384 [TBL] [Abstract][Full Text] [Related]
8. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. Safaeian M; Sampson JN; Pan Y; Porras C; Kemp TJ; Herrero R; Quint W; van Doorn LJ; Schussler J; Lowy DR; Schiller J; Schiffman MT; Rodriguez AC; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; Kreimer AR; J Natl Cancer Inst; 2018 Feb; 110(2):205-12. PubMed ID: 28954299 [TBL] [Abstract][Full Text] [Related]
9. Cervical, anal and oral HPV in an adolescent inner-city health clinic providing free vaccinations. Schlecht NF; Burk RD; Nucci-Sack A; Shankar V; Peake K; Lorde-Rollins E; Porter R; Linares LO; Rojas M; Strickler HD; Diaz A PLoS One; 2012; 7(5):e37419. PubMed ID: 22624027 [TBL] [Abstract][Full Text] [Related]
10. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. Lang Kuhs KA; Gonzalez P; Rodriguez AC; van Doorn LJ; Schiffman M; Struijk L; Chen S; Quint W; Lowy DR; Porras C; DelVecchio C; Jimenez S; Safaeian M; Schiller JT; Wacholder S; Herrero R; Hildesheim A; Kreimer AR; J Infect Dis; 2014 Dec; 210(12):1890-9. PubMed ID: 24958910 [TBL] [Abstract][Full Text] [Related]
11. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Kreimer AR; Rodriguez AC; Hildesheim A; Herrero R; Porras C; Schiffman M; González P; Solomon D; Jiménez S; Schiller JT; Lowy DR; Quint W; Sherman ME; Schussler J; Wacholder S; J Natl Cancer Inst; 2011 Oct; 103(19):1444-51. PubMed ID: 21908768 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594 [TBL] [Abstract][Full Text] [Related]
13. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G; Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Kreimer AR; Struyf F; Del Rosario-Raymundo MR; Hildesheim A; Skinner SR; Wacholder S; Garland SM; Herrero R; David MP; Wheeler CM; ; González P; Jiménez S; Lowy DR; Pinto LA; Porras C; Rodriguez AC; Safaeian M; Schiffman M; Schiller JT; Schussler J; Sherman ME; ; Bosch FX; Castellsague X; Chatterjee A; Chow SN; Descamps D; Diaz-Mitoma F; Dubin G; Germar MJ; Harper DM; Lewis DJ; Limson G; Naud P; Peters K; Poppe WA; Ramjattan B; Romanowski B; Salmeron J; Schwarz TF; Teixeira JC; Tjalma WA; ; Lancet Oncol; 2015 Jul; 16(7):775-86. PubMed ID: 26071347 [TBL] [Abstract][Full Text] [Related]
16. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. Tota JE; Struyf F; Merikukka M; Gonzalez P; Kreimer AR; Bi D; Castellsagué X; de Carvalho NS; Garland SM; Harper DM; Karkada N; Peters K; Pope WAJ; Porras C; Quint W; Rodriguez AC; Schiffman M; Schussler J; Skinner SR; Teixeira JC; Wheeler CM; Herrero R; Hildesheim A; Lehtinen M; J Natl Cancer Inst; 2017 Jan; 109(7):. PubMed ID: 28132019 [TBL] [Abstract][Full Text] [Related]
18. The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial. Bosch FX; de Sanjose S; Castellsague X Cancer Discov; 2011 Oct; 1(5):377-80. PubMed ID: 22586628 [TBL] [Abstract][Full Text] [Related]
19. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL; Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420 [TBL] [Abstract][Full Text] [Related]
20. Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol. López-Codony V; de Andrés-Pablo Á; Ferrando-Díez A; Fernández-Montolí ME; López-Querol M; Tous S; Ortega-Expósito C; Torrejón-Becerra JC; Pérez Y; Ferrer-Artola A; Sole-Sedeno JM; Grau C; Rupérez B; Saumoy M; Sánchez M; Peremiquel-Trillas P; Bruni L; Alemany L; Bosch FX; Pavón MA PLoS One; 2024; 19(5):e0304080. PubMed ID: 38768231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]